Amyris Proclaims Worth of $ 300.0 Million Public Providing (Secondary and Major) of Widespread Shares

EMERYVILLE, Calif., April 9, 2021 / PRNewswire / – Amyris, Inc. (Nasdaq: AMRS) (“Amyris”), a number one artificial biotechnology firm energetic within the clear well being and wonder markets by way of its manufacturers normal public and a number one provider of sustainable and pure substances, in the present day introduced the value of a subscribed public providing of a complete of 19,047,619 shares of its frequent inventory at a public providing worth of $ 15.75 per share, which consists of a secondary providing of 11,390,797 shares on the market, within the combination, by DSM Worldwide BV and the subsidiaries of Vivo Capital LLC (the promoting shareholders) and seven,656,822 shares on the market by Amyris.

Amyris is not going to obtain any proceeds from the sale of shares below the secondary providing by the promoting shareholders. The gross proceeds of the providing to Amyris, earlier than deduction of the low cost and any subscription commissions and estimated providing prices, and assuming that there is no such thing as a train of the underwriters’ possibility to purchase further shares, is anticipated to quantity to roughly $ 120.6 million.

The promoting shareholders and Amyris have granted the underwriters a 30-day choice to buy as much as 2,857,142 further frequent shares of Amyris on the public providing worth, much less subscription rebates and commissions. On this 30-day possibility, as much as 1,708,619 shares could be bought by the promoting shareholders and as much as 1,148,523 shares could be bought by Amyris. The provide is anticipated to shut on or round April 13, 2021, topic to the satisfaction of customary closing circumstances.

JP Morgan Securities LLC and Cowen and Firm, LLC are performing as co-bookrunners for the providing.

The general public providing is being made in accordance with an computerized registration assertion on Kind S-3 which was filed by Amyris with the US Securities and Change Fee (the “SEC”) on April 7, 2021, and is mechanically entered into pressure upon submitting. The Supply has been made solely by means of a preliminary prospectus complement and associated prospectus referring to the Supply which have been filed with the SEC and can be found on the SEC’s web site at A ultimate prospectus complement will probably be filed with the SEC, a replica of which can be obtained, when out there, from JP Morgan Securities LLC, c / o Broadridge Monetary Options, 1155 Lengthy Island Avenue, Edgewood, NY 11717, by way of phone at (866) 803-9204, or by e-mail at [email protected]; or Cowen and Firm, LLC, c / o Broadridge Monetary Options, Attn .: Prospectus Division, 1155 Lengthy Island Avenue, Edgewood, NY 11717, by telephone at (833) 297-2926, or by e mail at PostSaleManualRequests @

This press launch doesn’t represent a suggestion to promote or the solicitation of a suggestion to purchase, and there will probably be no sale of such securities in any state or jurisdiction the place such provide, solicitation or sale could be unlawful earlier than registration or qualification below the securities legal guidelines of these states or jurisdictions.

About Amyris

Amyris (Nasdaq: AMRS) is a scientific and technological chief within the analysis, improvement and manufacturing of sustainable substances for the Clear Well being & Magnificence and Flavors & Fragrances markets. Amyris makes use of a formidable array of proprietary applied sciences together with leading edge machine studying, robotics and synthetic intelligence. Our substances are included in over 3,000 merchandise from the world’s main manufacturers, reaching over 200 million customers. Amyris is proud to personal three client manufacturers – all constructed round its No Compromise® promise of fresh substances: Biossance® clear magnificence skincare, Pipette® clear child skincare and Purecane ™, a zero-calorie sweetener naturally derived from cane to sugar. Amyris, the Amyris emblem, No Compromise, Biossance, Pipette, and Purecane are logos or registered logos of Amyris, Inc. in the US and / or different international locations.

Use of forward-looking statements

This press launch incorporates “forward-looking statements” inside the that means of the Securities Act of 1933, as amended, the Securities Change Act of 1934, as amended, and the secure harbor provisions of the Personal Securities Litigation Reform Act of 1995 , together with, however not restricted to, statements concerning the product anticipated to be acquired by Amyris and the timing of the closing of the provide. These forward-looking statements could also be accompanied by phrases reminiscent of “goal”, “anticipate”, “imagine”, “could”, “estimate”, “count on”, “foresee”, “goal”, “intend” , “Might,” “might”, “plan”, “potential”, “potential”, “will”, “would”, and different phrases and phrases having the same that means. These statements contain dangers and uncertainties which might trigger precise outcomes to vary materially from these mirrored in our public filings, together with, with out limitation, dangers which can be past our whole management; dangers related to present and potential delays, work stoppages or provide chain disruptions brought on by the coronavirus pandemic; and the opposite dangers and uncertainties described within the Danger Elements part of our annual report on Kind 10-Ok filed with the SEC on March 5, 2021 and others reviews filed with the SEC, the provisional prospectus complement re and the prospectus referring to the general public providing and subsequent filings with the SEC. We assume no obligation to publicly replace any forward-looking statements, written or oral, that could be made infrequently, whether or not on account of new data, future developments or in any other case.

Cision Present unique content material to obtain multimedia:

SOURCE Amyris, Inc.

Supply hyperlink

Comments are closed.